Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.

TitleWeekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.
Publication TypeJournal Article
Year of Publication2013
AuthorsYu K-D, Liu G-Y, Chen C-M, Li J-W, Wu J, Lu J-S, Shen Z-Z, Shao Z-M
JournalThe oncologist
Volume18
Issue5
Pagination511-7
Date Published2013
Abstract

The efficacy and tolerability of two different schedules of paclitaxel, carboplatin, and trastuzumab (PCarH) for HER2-positive, locally aggressive (stage IIB-IIIC) breast cancers were evaluated in this phase II trial.

DOI10.1074/jbc.M113.506568
Alternate JournalOncologist